Both drugs work by inhibiting 5-alpha reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT), the androgen principally responsible for driving follicle miniaturisation in AGA. The difference is which isoforms of the enzyme each drug targets. Finasteride selectively inhibits type II 5-alpha reductase, the isoform predominantly expressed in hair follicles, prostate, and seminal vesicles. Dutasteride inhibits both type I and type II, and its affinity for type II is itself several times greater than finasteride's.

Type I 5-alpha reductase is expressed more broadly, including in skin and sebaceous glands, and its specific contribution to scalp DHT levels in AGA is smaller than type II's but not zero. Dutasteride's inhibition of this additional pathway, combined with its greater potency at the shared type II target, is the mechanistic basis for its more complete DHT suppression. The full androgen pathway is covered in the article on DHT and the follicle.

Oral finasteride at the standard 1mg daily dose reduces serum DHT by approximately 65 to 70%. Oral dutasteride at 0.5mg daily reduces serum DHT by approximately 90%, and some data suggests suppression can reach 94 to 95% depending on dosing and duration. This is a substantial pharmacological difference, not a marginal one, and it is the basis for essentially all of the comparative claims made about the two drugs.

Greater DHT suppression is not automatically better in every respect. It is the likely explanation for dutasteride's generally stronger efficacy data, and it is also the likely explanation for its correspondingly larger systemic side effect signal in some studies. The two are linked: a drug that more completely removes a hormonal signal will tend to produce a bigger version of both the intended effect and the associated risks.

Several head-to-head randomised trials have compared oral dutasteride directly against oral finasteride, and a systematic review pooling their results has been published. The consistent direction of the evidence favours dutasteride on hair count and density outcomes, though the size of the advantage varies by study.

Taken together, the direction of the trial evidence is fairly consistent: dutasteride outperforms finasteride on objective hair count and density measures in most head-to-head comparisons. What the individual trials differ on is the size of that advantage, and several use doses of dutasteride (2.5mg in the Olsen study, for instance) well above the 0.5mg most commonly used in current off-label AGA prescribing, which should be kept in mind when reading the magnitude of any single result.

A substantial minority of finasteride users do not achieve the level of improvement they hoped for, and others see initial response plateau or decline over years of use. One study specifically investigated switching in this scenario: 31 Korean men with AGA who had not responded to six months of oral finasteride 1mg were transitioned to dutasteride 0.5mg daily, and after a further six months showed a 10.3% increase in hair density and an 18.9% increase in hair thickness.

This is a plausible mechanism-driven outcome rather than a surprising one: if type I 5-alpha reductase activity or incomplete type II suppression was contributing to a given person's DHT-driven miniaturisation, moving to a drug that addresses both would be expected to help where finasteride alone did not. It does not mean dutasteride will rescue every finasteride non-responder; some proportion of AGA progression is unrelated to residual DHT activity and would not respond to any degree of 5-AR inhibition regardless of isoform coverage.

Finasteride has an elimination half-life of roughly six to eight hours. Dutasteride's elimination half-life is measured in weeks, reported in the region of four to five weeks at steady state, meaning it can take several months for the drug to substantially clear the body after discontinuation, compared to a day or two for finasteride.

Both drugs share broadly the same side effect category: sexual side effects (reduced libido, erectile dysfunction, ejaculatory changes) are the most commonly reported, alongside a smaller incidence of gynaecomastia and other effects related to systemic hormonal shift. The pooled data in the Zhou et al. meta-analysis found a broadly comparable overall safety profile between the two drugs, though individual trials have reported somewhat higher rates of certain sexual side effects with dutasteride, plausibly linked to its greater degree of DHT suppression.

Reports of persistent symptoms following discontinuation exist for both drugs, generating a body of literature around post-finasteride syndrome specifically, with comparable concerns raised for dutasteride given its similar mechanism, longer half-life, and more complete hormonal suppression. The precise incidence and causal mechanisms of these persistent effects remain areas of ongoing investigation for both drugs, and the same epistemic caution applies to claims about either.

Neither drug's side effect risk is eliminated by choosing the other. Someone who experiences sexual side effects on finasteride is not guaranteed to avoid them on dutasteride, and dutasteride's greater potency means that, if side effects do occur, they may take considerably longer to resolve given the drug's slower clearance.

Beyond DHT suppression, both finasteride and dutasteride may influence neurosteroid synthesis through inhibition of 5-alpha reductase. One neurosteroid of interest is allopregnanolone, which plays a role in GABAergic signalling. Because dutasteride inhibits both type I and type II 5-alpha reductase, whereas finasteride primarily inhibits type II, some researchers have suggested the two drugs may differ in their effects on neurosteroid metabolism. However, the clinical significance of this remains an active area of research and has not been fully established.

Finasteride 1mg is licensed in the UK specifically for male pattern hair loss. Dutasteride is licensed for benign prostatic hyperplasia; its use for AGA is off-label, prescribed at the clinician's discretion based on the accumulated trial evidence rather than a formal hair loss indication. This does not mean dutasteride is unsafe or inappropriate for hair loss, off-label prescribing is common and well-established practice in dermatology, but it does mean the regulatory pathway and the volume of manufacturer-sponsored safety monitoring specific to the hair loss indication differ between the two drugs.

Both are prescription-only medications regardless of route. Both carry the same reproductive contraindication: neither should be handled by women who are pregnant or may become pregnant, due to the risk of feminisation of a male foetus. This decision, like the topical route decisions covered elsewhere in this series, should be made with a prescribing clinician who can weigh treatment history, risk tolerance, and response so far.

Finasteride is generally the more conservative starting point: a licensed indication specifically for hair loss, a shorter half-life that allows faster reversal if side effects occur, and a much larger and longer-running safety database. It is the more sensible first choice for most people beginning DHT suppression for the first time.

Dutasteride is generally considered when finasteride has been tried and found insufficient, either through non-response or plateaued results, or by someone who has weighed the trial evidence and, with their prescriber, decided the stronger efficacy signal is worth the longer half-life and off-label status. It is not inherently the "better" choice for everyone; it is the higher-potency option with a correspondingly larger commitment given how slowly it clears.

For people specifically motivated by minimising systemic exposure regardless of which drug they choose, the topical route is worth discussing with a prescriber for either compound. The evidence bases differ substantially between the two: topical finasteride has decades of research including a Phase 3 RCT, covered in topical vs oral finasteride, while topical dutasteride's evidence is newer and thinner, covered in topical vs oral dutasteride. The broader AGA treatment landscape, including how 5-AR inhibition fits alongside minoxidil and topical actives such as the 1% AHK-Cu Hair and Scalp Serum, is covered in androgenetic alopecia: what it is, what causes it, and what the options are.

This article is provided for educational purposes and does not constitute medical advice. Both finasteride and dutasteride are prescription-only medications in the UK; dutasteride is used off-label for hair loss. Consult a qualified healthcare professional before starting, switching, or stopping either medication. AmpleLab products are cosmetic formulations and are not intended to diagnose, treat, cure, or prevent any condition.

AmpleLab.